Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson speaks to Proactive following the company's AGM.
It's recently achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin tissue through an innovative processing technique.
''It's important to me to get the point across that the product is coming to market'', he says.
''There's no speculation around whether we will develop a product or whether that product will get there''.
''It's now moving into its FDA studies and will be into its regulatory approval studies for commercialisation''.
''On the back of that not only is it viable but the data is so compelling .... it is significantly better than what is currently in the market''.